Alzheimer’s disease (AD) is characterized by accumulation of amyloid-β (Aβ) species and deposition of senile plaques (SPs). Clinical trials with the anti-Aβ antibody aducanumab have been completed recently.
Objective:
To characterize the proteomic profile of SPs and surrounding tissue in a mouse model of AD in 10-month-old tgAPPPS1-21 mice after chronic treatment with aducanumab for four months with weekly dosing (10 mg/kg).
Methods:
After observing significant reduction of SP numbers in hippocampi of aducanumab-treated mice, we applied a localized proteomic analysis by combining laser microdissection and liquid chromatography-tandem mass spectrometry (LC-MS/MS) of the remaining SPs in hippocampi. We microdissected three subregions, containing SPs, SP penumbra level 1, and an additional penumbra level 2 to follow the proteomic profile as gradient.
Results:
In the aducanumab-treated mice, we identified 17 significantly regulated proteins that were associated with 1) mitochondria and metabolism (ACAT2, ATP5J, ETFA, EXOG, HK1, NDUFA4, NDUFS7, PLCB1, PPP2R4), 2) cytoskeleton and axons (ADD1, CAPZB, DPYSL3, MAG), 3) stress response (HIST1H1C/HIST1H1D, HSPA12A), and 4) AβPP trafficking/processing (CD81, GDI2). These pathways and some of the identified proteins are implicated in AD pathogenesis. Proteins associated with mitochondria and metabolism were mainly upregulated while proteins associated with AβPP trafficking/processing and stress response pathways were mainly downregulated, suggesting that aducanumab could lead to a beneficial proteomic profile around SPs in tgAPPPS1-21 mice.
Conclusion:
We identified novel proteomic patterns of SPs and surrounding tissue indicating that chronic treatment with aducanumab could inhibit Aβ toxicity and increase phagocytosis and cell viability.
MastersCL, SimmsG, WeinmanNA, MulthauptG, McdonaldBL (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A82, 4245–4249.
2.
JackCJ, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
3.
ZhangY, LeeDHS (2011) Sink hypothesis and therapeutic strategies for attenuating Aβ levels. Neuroscience17, 163–173.
4.
BohrmannB, BaumannK (2012) Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis28, 49–69.
BacskaiBJ, KajdaszST, McLellanME, GamesD, SeubertP, SchenkD, HymanBT (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci22, 7873–7878.
7.
ArndtJW, QianF, SmithBA, QuanC, KilambiKP, BushMW, WalzT, PepinskyRB, BussièreT, HamannS, CameronTO, WeinrebPH (2018) Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep8, 6412.
8.
SchneiderL (2020) A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol19, 111–112.
BerridgeMJ (2014) Calcium regulation of neural rhythms, memory and Alzheimer’s disease. J Physiol592, 281–293.
11.
DrummondE, NayakS, FaustinA, PiresG, HickmanRA, AskenaziM, CohenM, HaldimanT, KimC, HanX, ShaoY, SafarJG (2017) Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease. Acta Neuropathol133, 933–954.
12.
XiongF, GeW, MaC (2019) Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer’s disease. Alzheimers Dement15, 429–440.
13.
CarlredL, MichnoW, KayaI, SjövallP, SyvänenS, HanriederJ (2016) Probing amyloid-β pathology in transgenic Alzheimer’s disease (tgArcSwe) mice using MALDI imaging mass spectrometry. J Neurochem138, 469–478.
14.
BastrupJ, BirkelundS, AsuniAA, VolbrachtC, StensballeA (2019) Dual strategy for reduced signal-suppression effects in matrix-assisted laser desorption/ionization mass spectrometry imaging. Rapid Commun Mass Spectrom33, 1711–1721.
15.
BastrupJ, KastaniegaardK, AsuniAA, VolbrachtC, StensballeA (2020) Proteomic and unbiased post-translational modification profiling of amyloid plaques and surrounding tissue in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis73, 393–411.
VizcaínoJA, CsordasA, Del-ToroN, DianesJA, GrissJ, LavidasI, MayerG, Perez-RiverolY, ReisingerF, TernentT, XuQ, WangR, HermjakobH (2016) 2016 update of the PRIDE database and its related tools. Nucleic Acids Res44, D447–D456.
20.
DekkersG, BentlageAEH, StegmannTC, HowieHL, Lissenberg-ThunnissenS, ZimringJ, RispensT, VidarssonG (2017) Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs9, 767–773.
21.
Sanz-BlascoS, ValeroRA, Rodríguez-CrespoI, VillalobosC, NúñezL (2008) Mitochondrial Ca2+overload underlies Aβ oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS One3, e2718.
KaoPF, DavisDA, BaniganMG, VanderburgCR, SeshadriS, DelalleI (2010) Modulators of cytoskeletal reorganization in CA1 hippocampal neurons show increased expression in patients at mid-stage Alzheimer’s disease. PLoS One5, e13337.
24.
BehrendtG, BaerK, BuffoA, CurtisMA, FaullRL, ReesMI, GötzM, DimouL (2013) Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia61, 273–286.
25.
MitewS, KirkcaldieMTK, HallidayGM, ShepherdCE, VickersJC, DicksonTC (2010) Focal demyelination in Alzheimer’s disease and transgenic mouse models. Acta Neuropathol119, 567–577.
26.
ZhangQ, MaC, GearingM, WangPG, ChinL-S, LiL (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease. Acta Neuropathol Commun6, 19.
27.
SeipoldL, SaftigP (2016) The emerging role of tetraspanins in the proteolytic processing of the amyloid precursor protein. Front Mol Neurosci9, 1–7.
28.
WakabayashiT, CraessaertsK, BammensL, BentahirM, BorgionsF, HerdewijnP, StaesA, TimmermanE, VandekerckhoveJ, RubinsteinE, BoucheixC, GevaertK, De StrooperB (2009) Analysis of the γ-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nat Cell Biol11, 1340–1346.
29.
Di DomenicoF, SultanaR, BaroneE, PerluigiM, CiniC, MancusoC, CaiJ, PierceWM, ButterfieldDA (2011) Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer’s disease subjects. J Proteomics74, 1091–1103.
30.
ShishevaA, ChinniSR, DeMarcoC (1999) General role of GDP dissociation inhibitor 2 in membrane release of Rab proteins: Modulations of its functional interactions by in vitro and in vivoandstructural modifications. Biochemistry38, 11711–11721.
31.
HamS, KimTK, HongH, KimYS, TangY-P, ImH-I (2018) Big data analysis of genes associated with neuropsychiatric disorders in an Alzheimer’s disease animal model. Front Neurosci12, 1–12.
32.
GarridoC, GurbuxaniS, RavagnanL, KroemerG (2001) Heat shock proteins: Endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun286, 433–442.
33.
MadsenP, IsaksenTJ, SiupkaP, TóthAE, NyegaardM, GustafsenC, NielsenMS (2019) HSPA12A targets the cytoplasmic domain and affects the trafficking of the Amyloid Precursor Protein receptor SorLA. Sci Rep9, 611.
AbidN, NaseerM, KimM (2019) Comparative gene-expression analysis of Alzheimer’s disease progression with aging in transgenic mouse model. Int J Mol Sci20, 1219.
36.
SaraivaLM, Seixas da SilvaGS, GalinaA, Da-SilvaWS, KleinWL, FerreiraST, De FeliceFG (2010) Amyloid-β triggers the release of neuronal hexokinase 1 from mitochondria. PLoS One5, e15230.
37.
CaspersenC, WangN, YaoJ, SosunovA, ChenX, LustbaderJW, XuHW, SternD, McKhannG, Du YanS (2005) Mitochondrial Aβ: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J19, 2040–2041.
38.
ManczakM, AnekondaTS, HensonE, ParkBS, QuinnJ, ReddyPH (2006) Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet15, 1437–1449.
39.
KuchibhotlaK V., GoldmanST, LattaruloCR, WuH-Y, HymanBT, BacskaiBJ (2008) Aβ plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron59, 214–225.
40.
GibsonGE, ShiQ (2010) A mitocentric view of Alzheimer’s disease suggests multi-faceted treatments. J Alzheimers Dis20, S591–S607.
